HDAC6 and leukemia: Our results strongly indicate that LASSBio-2208, despite its potency in the nanomolar range on the PI3K and HDAC-6 targets (Figure 1), has inadequate physicochemical properties, reflecting a low permeation and absorption profile, with impacts on its cytotoxic and antiproliferative potency on human solid tumour and leukaemia cell lines.